255
29. Brancato R, Introini U, Pierro L, Setaccioli M, Forti M, Bolognesi G,
etal. Optical coherence tomography (OCT) in retinal angiomatous
proliferation (RAP). Eur J Ophthalmol 2002;12:467-72
30. Chen TC, Cense B, Pierce MC, Nassif N, Park BH, Yun SH, White
BR, Bouma BE, Tearney GJ, de Boer JF. Spectral domain optical
coherence tomography: ultra-high speed, ultra-high resolution
ophthalmic imaging. Arch Ophthalmol 2005;123:1715-20
31. Han IC, Jaffe GJ. Comparison of spectral- and time-domain optical
coherence tomography for retinal thickness measurements in healthy
and diseased eyes. Am J Ophthalmol 2009;147:847-58
33. Mylonas G, Ahlers C, Malamos P, Golbaz I, Deak G, Schuetze
C, Sacu S, Schmidt-Erfurth U. Comparison of retinal thickness
measurements and segmentation performance of four different
spectral and time domain OCT devices in neovascular age-related
macular degeneration. Br J Ophthalmol 2009;93:1453-60
34. Patel PJ, Chen FK, da Cruz L, Tufail A. Segmentation error in Stratus
optical coherence tomography for neovascular age-related macular
degeneration. Invest Ophthalmol Vis Sci 2009;50:399-404
35. Ghazi NG, Kirk T, Allam S, Yan G. Quantification of error in optical
coherence tomography central macular thickness measurement in wet
age-related macular degeneration. Am J Ophthalmol 2009;148:90-6
36. Krebs I, Falkner-Radler C, Hagen S, Haas P, Brannath W, Lie S,
Ansari-Shahrezaei S, Binder S. Quality of the threshold algorithm in
age-related macular degeneration: Stratus versus Cirrus OCT. Invest
Ophthalmol Vis Sci 2009;50:995-1000
37. Sayanagi K, Sharma S, Yamamoto T, Kaiser PK. Comparison of
spectral-domain versus time-domain optical coherence tomography
in management of age-related macular degeneration with
ranibizumab. Ophthalmology 2009;116:947-55
38. Krebs I, Ansari-Shahrezaei S, Goll A, Binder S. Activity of
neovascular lesions treated with bevacizumab: comparison between
optical coherence tomography and fluorescein angiography. Graefes
Arch Clin Exp Ophthalmol 2008;246:811-5
39. Malamos P, Sacu S, Georgopoulos M, Kiss C, Pruente C, Schmidt-
Erfurth U. Correlation of high-definition optical coherence
tomography and fluorescein angiography imaging in neovascular
macular degeneration. Invest Ophthalmol Vis Sci 2009;50:4926-33
40. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging
spectral-domain optical coherence tomography. Am J Ophthalmol.
2008;146:496-500
41. Spaide RF. Enhanced depth imaging optical coherence tomography
of retinal pigment epithelial detachment in age-related macular
degeneration. Am J Ophthalmol 2009;147:644-52
42. Margolis R, Spaide RF. A pilot study of enhanced depth imaging
optical coherence tomography of the choroid in normal eyes. Am J
Ophthalmol 2009;147:811-5
43. Salinas-Alamán A, García-Layana A, Maldonado MJ, Sainz-Gómez
C, Alvárez-Vidal A. Using optical coherence tomography to monitor
photodynamic therapy in age related macular degeneration. Am J
Ophthalmol 2005;140:23-8
44. van Velthoven ME, de Smet MD, Schlingemann RO, Magnani M,
Verbraak FD. Added value of OCT in evaluating the presence of
leakage in patients with age-related macular degeneration treated with
PDT. Graefes Arch Clin Exp Ophthalmol 2006;244:1119-23
45. Talks J, Koshy Z, Chatzinikolas K. Use of optical coherence
tomography, fluorescein angiography and indocyanine green
angiography in a screening clinic for wet age-related macular
degeneration. Br J Ophthalmol 2007;91:600-1
46. Brar M, Kozak I, Cheng L, Bartsch DU, Yuson R, Nigam N, Oster
SF, Mojana F, Freeman WR. Correlation between spectral-domain
optical coherence tomography and fundus autofluorescence at the
margins of geographic atrophy. Am J Ophthalmol 2009;148:439-44
47. Stopa M, Bower BA, Davies E, Izatt JA, Toth CA. Correlation of
pathologic features in spectral domain optical coherence tomography
with conventional retinal studies. Retina 2008;28:298-308
48. Talks J, Koshy Z, Chatzinikolas K. Use of optical coherence
tomography, fluorescein angiography and indocyanine green
angiography in a screening clinic for wet age-related macular
degeneration. Br J Ophthalmol 2007;91:600-1
49. Brar M, Kozak I, Cheng L, Bartsch DU, Yuson R, Nigam N, Oster
SF, Mojana F, Freeman WR. Correlation between spectral-domain
optical coherence tomography and fundus autofluorescence at the
margins of geographic atrophy. Am J Ophthalmol 2009;148:439-
44
50. Lujan BJ, Rosenfeld PJ, Gregori G, Wang F, Knighton RW, Feuer
WJ, Puliafito CA. Spectral domain optical coherence tomographic
imaging of geographic atrophy. Ophthalmic Surg Lasers Imaging
2009;40:96-101
51. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro
H, Schneider S, Acharya NR. Ranibizumab for predominantly
classic neovascular age-related macular degeneration: subgroup
analysis of first-year ANCHOR results. Am J Ophthalmol
2007;144:850-857
52. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev
T et als; ANCHOR Study Group. Ranibizumab versus
verteporfin photodynamic therapy for neovascular age-related
macular degeneration: Two-year results of the ANCHOR study.
Ophthalmology 2009;116:57-65
53. Kaiser PK, Blodi BA, Shapiro H, Acharya NR et als; MARINA Study
Group. Angiographic and optical coherence tomographic results of the
MARINA study of ranibizumab in neovascular age-related macular
degeneration. Ophthalmology 2007;114:1868-75
54. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S,
Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M.
An optical coherence tomography-guided, variable dosing regimen
with intravitreal ranibizumab (Lucentis) for neovascular age-related
macular degeneration. Am J Ophthalmol 2007;143:566-83
55. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer
W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen
with intravitreal ranibizumab for neovascular age-related macular
degeneration: year 2 of the PrONTO Study. Am J Ophthalmol
2009;148:43-58
56. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider
S, Shams N. Randomized, double-masked, sham-controlled trial of
ranibizumab for neovascular age-related macular degeneration: PIER
Study year 1. Am J Ophthalmol 2008;145:239-248
57. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Pruente C, Schmidt-
Erfurth UM, Tano Y, Wolf S. Ranibizumab (Lucentis) in neovascular
age-related macular degeneration: evidence from clinical trials. Br J
Ophthalmol 2009; Publicación electrónica, en prensa.
OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION
